TCBP News and Press, TC BioPharm (Holdings) plc From 02/13/23

TC BioPharm to Reschedule Shareholder Update Call and Webcast PR Newswire Conference Call to be held on Tuesday, February 21 st , 2023 at Noon ET EDINBURGH, Scotland , Feb. 13, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm"...

TC BioPharm Announces Successful Dosing of Final Patient in ACHIEVE Safety Cohort PR Newswire Phase 2B Clinical Trial Evaluating Omnimmune ® in AML Patients EDINBURGH, Scotland , Feb. 7, 2023 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("T...

TC BioPharm Announces Hiring of Chief Clinical Officer Bree Harlin to Lead Global Clinical Division PR Newswire Will oversee expansion of U.S. FDA Clinical Tria ls EDINBURGH, Scotland , Jan. 30, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ...

TC BioPharm to Host Shareholder Update Call PR Newswire Conference Call to be held on Monday, February 20 th , 2023 at 10:00 am ET EDINBURGH, Scotland , Jan. 20, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Compan...

TC Biopharm ( NASDAQ: TCBP ) has received Nasdaq notice indicating the  company has not regained compliance with the rule of $35M minimum market value of listed securities. The company on July 15,2022 had received written Nasdaq notice indicating that the company wa...

Palm Beach, FL – January 19, 2023 – FinancialNewsMedia.com News Commentary – Gamma Delta T Cell Therapy represents one of the most promising T Cell therapies in clinical development. The introduction of T cell-based immunotherapy has greatly revolutionized the par...

TC BioPharm Receives Notice of Non-compliance with NASDAQ's Listing Rule 5550(b)(1) PR Newswire EDINBURGH, Scotland , Jan. 19, 2023 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), has received writte...

TC Biopharm ( NASDAQ: TCBP ) is trading 18.5% higher premarket after it announced a strategic collaboration with The University of Texas MD Anderson Cancer Center to test on how gamma-delta T cells work in oncology settings. Under the collaboration, MD Anderson's clinical tria...

TC BioPharm Announces Strategic Collaboration to Advance Gamma Delta T Cells in Oncology PR Newswire Endeavor to focus on expanding understanding of gamma-delta T cells in oncological settings EDINBURGH, Scotland , Jan. 17, 2023 /PRNewswire/ -- TC B...

TC Biopharm press release ( NASDAQ: TCBP ): 1H GAAP EPS of $1.13. Revenue of $1.2M. Cash and cash equivalents were £6.0 million or $7.3 million as of June 30, 2022 compared to £1.6 million as of December 31, 2021. For further details see: TC Biopharm GAAP E...